PO.TB10.18 · 肿瘤生物学

细胞亲合力(Cell Avidity):通过量化细胞-细胞及细胞-蛋白相互作用强度来理解治疗作用机制的新一代细胞结合分析

Cell Avidity: The Next-Gen cell binding assay to understand therapeutic mechanism of action through quantifying cell-cell and cell-protein interaction strength

编号 4930 展板 18 时间 4/21 09:00–12:00 区域 Section 30 主讲 Keith Bailey, PhD
分会场 Novel Experimental Platforms and Causal Inference
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Keith Bailey1, Riley Pihl1, Michael SAVAGE2, Trey Simpson3

1LUMICKS, Amsterdam, Netherlands,2LUMICKS, New York, NY,3LUMICKS, Boston, MA

摘要 Abstract

中文摘要
尽管亲和力、细胞因子分泌和细胞毒性等传统分析在分子水平上提供了有价值的数据,但这些信息不足以充分表征和筛选最佳的细胞疗法。人们对于驱动功能性过程的生物物理性细胞-细胞相互作用仍缺乏理解。 方法:细胞亲合力(cell avidity),即效应细胞与其靶标之间多价相互作用的整合强度,有助于阐明候选治疗药物的作用机制。我们的细胞亲合力平台利用非接触式力对这些相互作用的细胞对施加挑战,并量化效应细胞与靶细胞之间的结合强度,从而在生理背景下区分有效结合与无效的细胞结合。这一生物物理指标提供了洞察细胞结合特征的独特视角,可用于探究结合效力、选择性、敏感性和动力学。 结果:在此,我们回顾了近期展示研究人员如何运用细胞亲合力的出版物:• 微调CAR-T细胞的亲和力/细胞亲合力,以减轻肾细胞癌中的靶向非肿瘤(on-target off-tumor)毒性。• 评估Venetoclax治疗对NK细胞的影响,发现其改善了细胞骨架重塑和溶细胞颗粒极化,从而促成更高效的免疫突触(IS),增强了NK细胞介导的对AML细胞的杀伤。• 对双特异性T细胞衔接子进行格式微调,以增强对肾细胞癌的疗效。• 验证串联CAR-T细胞的结合机制,以克服肿瘤异质性。• 改造分泌T细胞衔接分子的CAR-T细胞,以克服胰腺腺癌中具有挑战性的肿瘤微环境。• 阐明靶向异质性实体瘤的串联CAR-T的作用机制。• 对肿瘤致敏的NK细胞进行细胞结合与功能表型分析。 结论:我们开发了一个细胞亲合力平台,能够对分子结合物和细胞产品(包括抗体、小分子和细胞疗法)进行表征和筛选。细胞亲合力提供关于效力、选择性、敏感性和动力学的全面信息,为细胞疗法的作用机制提供关键洞见。
查看英文原文 English abstract
While conventional assays such as affinity, cytokine secretion, and cytotoxicity provide valuable data at a molecular level, this information is insufficient to fully characterize and select the best cellular therapies. There is still a lack of understanding about the biophysical cell-cell interactions that drive functional processes. Methods: Cell avidity, the integrated strength of multivalent interactions between an effector cell and its target , can help elucidate the mechanism of action for therapeutic candidates. Our Cell Avidity platform challenges these interacting pairs using contactless force and quantifies the strength of binding between effector and target cells to distinguish productive from unproductive cell binding in a physiological context. This biophysical metric provides a unique view into cell binding characteristics to interrogate binding potency, selectivity, sensitivity, and kinetics . Results: Here, we review recent publications highlighting how researchers have used Cell Avidity to: • Fine-tune the affinity/cell avidity of CAR-T cells to mitigate on-target off-tumor toxicity in renal cell carcinoma. • Assess the impact of Venetoclax treatment on NK cells, finding improvements to cytoskeleton remodeling and lytic granule polarization, which contributed to a more efficient IS, enhancing NK cell-mediated killing of AML cells. • Format-tune bispecific T cell engagers to enhance efficacy against renal cell carcinoma • Validate binding mechanism of tandem CAR-T cells to overcome tumor heterogeneity • Engineer CAR-T cells secreting a T-cell engaging molecule to overcome a challenging tumor microenvironment in pancreatic adenocarcinoma. • Elucidate mechanism of action of tandem CAR-T targeting heterogenous solid tumors • Phenotype the tumor-primed NK cells for cell binding and function. Conclusions: We developed a Cell Avidity platform that enables the characterization and screening of molecular binders and cellular products, including antibodies, small molecules, and cell therapies. Cell Avidity provides comprehensive information on potency, selectivity, sensitivity, and kinetics, offering key insights into the mechanism of action for cell therapies.
利益披露 Disclosure
K. Bailey, None.. R. Pihl, None.

← 返回 AACR 2026 检索